- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Rakovina Therapeutics GAAP EPS of -C$0.01 | 1 | Seeking Alpha | ||
| Sa | Rakovina Therapeutics Inc: Rakovina Therapeutics ends 2023 with cash of $436,313 | 1 | Stockwatch | ||
| Sa | Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update | 302 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, April 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the "Company") a biopharmaceutical company committed to advancing new cancer therapies based... ► Artikel lesen | |
| 20.04. | Rakovina Therapeutics Inc: Rakovina Therapeutics 255,425 shares for debt | 1 | Stockwatch | ||
| 09.04. | Rakovina Therapeutics Inc: Rakovina presents data on kt-3000 series at AACR | 1 | Stockwatch | ||
| 09.04. | Rakovina Therapeutics Inc: Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today | 47 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), ("Rakovina" or the "Company"), a biopharmaceutical company dedicated to improving the lives... ► Artikel lesen | |
| 01.04. | Rakovina Therapeutics Inc: Rakovina hires Insight Capital for advisory services | 1 | Stockwatch | ||
| 01.04. | Rakovina Therapeutics Inc: Rakovina Therapeutics To Host Informational Webinar on April 3, 2024 | 1 | GlobeNewswire (USA) | ||
| 27.03. | Rakovina Therapeutics Inc: Rakovina signs agreement for Deep Docking AI platform | 1 | Stockwatch | ||
| 27.03. | Rakovina Therapeutics Inc: Rakovina Therapeutics Announces Strategic Pivot to AI | 1 | GlobeNewswire (USA) | ||
| 28.11.23 | Rakovina Therapeutics GAAP EPS of -$0.01 | 1 | Seeking Alpha | ||
| 28.11.23 | Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update | 176 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the "Company"), a biopharmaceutical company dedicated to improving the lives of cancer patients... ► Artikel lesen | |
| 27.11.23 | Rakovina Therapeutics Inc: Rakovina appoints Cherkasov as scientific adviser | 1 | Stockwatch | ||
| 20.11.23 | Rakovina Therapeutics Inc: Rakovina appoints Hamerlik as scientific adviser | 2 | Stockwatch | ||
| 20.11.23 | Rakovina Therapeutics Inc: Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member | 1 | GlobeNewswire (USA) | ||
| 29.08.23 | Rakovina Therapeutics Inc. Announces Q2 2023 Financial Results and Provides Corporate Update | 256 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the "Company"), a biopharmaceutical company dedicated to improving the lives of cancer patients... ► Artikel lesen | |
| 29.06.23 | Rakovina Therapeutics Inc: Rakovina Therapeutics Announces Results from 2023 Annual General Meeting | 199 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the "Company"), a biopharmaceutical company committed to advancing new cancer therapies based... ► Artikel lesen | |
| 31.05.23 | Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results and Provides Corporate Update | 304 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the "Company"), a biopharmaceutical company dedicated to improving the lives of cancer patients... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,585 | +1,29 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
| EVOTEC | 9,895 | +1,59 % | Evotec: War dieser Crash berechtigt? | Auf den ersten Blick wirkten die Ergebnisse des Vorjahres, die Evotec am Mittwochmorgen vorlegte, zwar nicht gerade gut, aber sie hätten nie und nimmer die Basis für einen Crash von 32 Prozent sein... ► Artikel lesen | |
| MORPHOSYS | 66,10 | -0,15 % | MorphoSys: Effekte der Novartis-Übernahmeofferte sorgen für hohen Quartalsverlust | Übernahmekandidat MorphoSys schließt das erste Quartal 2024 mit einem Verlust im fortgeführten Geschäft von 311 Millionen Euro ab nach 32,2 Millionen Euro Minus im Vorjahresquartal. Der Umsatz steigt... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 43,040 | -8,11 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,964 | +158,75 % | CytomX-Aktie +259%: Top-Empfehlung dreht völlig durch! | Mit der Aktie des Biotech-Unternehmens CytomX Therapeutics (WKN: A14158) knallt einer unserer Top-Tipps am Mittwoch in der Spitze um +259% von 1,63 US$ bis auf 5,85 US$ in die Höhe - bei absoluten Rekordumsätzen... ► Artikel lesen | |
| BIONTECH | 85,65 | +2,39 % | Moderna Aktie zieht BioNTech davon - Zahlen besser als erwartet | BioNTechs großer US-Konkurrent Moderna hat am Donnerstag Quartalszahlen vorgelegt - und der Aktienkurs des Biotech-Unternehmens reagiert äußerst positiv. Aktuell gewinnt der Titel an der US-Techbörse... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,705 | +4,38 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
| MODERNA | 119,46 | +15,60 % | Moderna to seek parity for RSV shot as rivals lead in market | ||
| JANUX THERAPEUTICS | 58,76 | +0,98 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| CULLINAN THERAPEUTICS | 27,650 | -1,60 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| CABALETTA BIO | 12,550 | +1,13 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,900 | +5,34 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| ARVINAS | 32,490 | +0,03 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,750 | -0,91 % | Arcutis Biotherapeutics, Inc.: Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 | ||
| DYNE THERAPEUTICS | 26,045 | +0,83 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen |
RAKOVINA THERAPEUTICS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
